Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1636 1681 1683 1685 1693
This examiner grants 56% of resolved cases
Mindy G Brown serves as an examiner in Tech Center 1600 and Art Unit 1634. She has managed 143 resolved cases, providing a reliable dataset for applicants to analyze. Her allowance rate is 55.9%, which provides a balanced outlook for applicants seeking a patent grant. This 55.9% figure indicates that more than half of the applications in her docket eventually reach allowance, requiring a focused prosecution effort.
The interview lift of 44.4% is a highly significant metric for this examiner. This 44.4% figure suggests that conducting an interview is a very effective way to increase the likelihood of an allowance. Practitioners should consider an interview as a primary tool for overcoming rejections and clarifying the invention's technical merits in Art Unit 1634. Additionally, the median days to allowance is 1012, which serves as a benchmark for the duration of successful prosecution. This 1012-day period is an important factor for applicants to consider when planning their strategy. With 143 resolved cases and a 55.9% allowance rate, the data highlights the importance of the 44.4% interview lift in navigating the 1012-day median prosecution cycle.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18404317 | SPATIAL ANALYSIS TO DETECT SEQUENCE VARIANTS | Non-Final OA | 10x Genomics, Inc. |
| 18612463 | HIGH THROUGHPUT NEWBORN SCREENING ASSAY FOR ANGELMAN AND PRADER-WILLI SYNDROMES | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18720587 | EXPANDED PANELS OF NUCLEIC ACID BIOMARKERS FOR PLACENTAL DYSFUNCTION | Non-Final OA | The Regents of the University of California |
| 19018456 | METHODS FOR EARLY DETECTION OF CANCER | Non-Final OA | GUARDANT HEALTH, INC. |
| 18465724 | TARGETED NEXT-GENERATION SEQUENCING VIA ANCHORED PRIMER EXTENSION | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18473971 | Resynthesis Kits and Methods | Non-Final OA | Illumina, Inc. |
| 17912008 | RESTORING PHASE IN MASSIVELY PARALLEL SEQUENCING | Non-Final OA | MGI Tech Co. Ltd. |
| 18943512 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | Non-Final OA | Exact Sciences Corporation |
| 18419082 | COMPOSITIONS AND METHODS FOR AMPLIFYING POLYNUCLEOTIDES | Non-Final OA | Illumina Cambridge Limited |
| 18546333 | BIOMARKERS FOR THE DIAGNOSIS OF BREAST CANCER | Non-Final OA | MAMMOGEN, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy